TESSA technology: a new paradigm in AAV manufacturing
Cell & Gene Therapy Insights 2020; 6(8), 1225
Published: 1 October 2020
Watch the video or read the poster to learn:
- Benefits and drawbacks of current AAV viral vector production methods
- How Tetracycline Enabled Self Silencing Adenovirus (TESSA) allows efficient, scalable AAV manufacture
- Results from studies comparing TESSA with conventional methods
We hope you enjoyed this FastFacts video. You can also view the summary PDF here.